Browse our previous newsletters to hear more from industry experts, urologists, innovations, and updates from Exosome Diagnostics.
June 2022: Biomarkers Accurately Inform Treatment Decisions in Localized Prostate Cancer
Dr. Judd Moul, urologist at the Duke Cancer Institute and Duke University Medical, highlighted his clinical experience with the ExoDx Prostate test which was approved for use at his institution in 2018. Liquid biomarkers, such as the ExoDx Prostate test, can be utilized as a secondary data point to share a man’s personal risk assessment to improve compliance to biopsy when needed.
July 2022: Urology Experts Discuss Use of the ExoDx™ Prostate Test (EPI) in Clinical Practice
We were delighted to see the ExoDx™ Prostate Test featured in a peer discussion among urology colleagues, led by Dr. Sanoj Punnen, in June’s edition of Urology Times. Panelists sought to address a theoretical patient’s medical history and it was widely agreed upon that another test should be performed.
August 2022: EPI Test highlighted in CJU's "How I Use It"
Urology experts Judd W. Moul, MD, and Grannum R. Sant, MD, share a “How I Use It” opinion piece in the Canadian Journal of Urology highlighting the real-world contemporary utilization of the ExoDx Prostate test in primary care and urology practices. The EPI test is one of the more frequently utilized liquid biomarkers for risk-stratification in men prior to initial and repeat (“prior negative”) prostate biopsy.